No lab-leak claim. No “Moderna did it” claim. Just a public-source timeline where the dates keep standing too close together in the elevator.
Last checked May 12, 2026 · not updated since · re-verify before quoting · sources ↓
Two dates, two days apart. One is a stock chart. One is a surveillance spreadsheet. Neither proves anything. Both are on the board.
The entire thesis fits in a tweet, which is exactly why it needs a source stack. Every line below is individually true. The vibe they make together is not evidence.
moderna bottomed nov 20
paho's hantavirus data window closed nov 22
moderna already had a hantavirus mrna program
argentina later becomes the andes virus story
not saying anything
just an annoying calendar
“mRNA Vaccines Against Hantavirus.” Assignee: University of Texas System. Federally funded research statement: none. Not a Moderna filing.
Google Patents ↗Research agreement for an mRNA-based hantavirus vaccine under Moderna’s mRNA Access program. Dated by the 2024 release as “last September.”
EurekAlert / Korea University ↗VIC-K and Moderna co-host a seminar on the hantavirus vaccine collaboration.
EurekAlert ↗Nature Communications paper. Two mRNA vaccines; the animal model was 100% lethal without protection. UTMB, Vanderbilt and Acuitas Therapeutics. Also not Moderna.
UTMB ↗ · Nature Comms ↗VIC-K supplied hantavirus antigen sequence information; Moderna supplied mRNA material made from it. VIC-K ran antigen expression studies and planned preclinical work.
EurekAlert ↗Per Scientific American, the Trump administration eliminated funding for a group (WAC-EID, part of CREID) whose Argentina pilot studied the type of hantavirus later behind the cruise outbreak. Roughly $100,000 likely dedicated to the Argentina study.
Scientific American ↗US20250127870A1. Inventors: Bukreyev, Garcia-Blanco, Kuzmin, Soto Acosta.
Google Patents ↗Strategic reset: seasonal vaccines, up to 10% revenue growth target for 2026, cost cuts, oncology and rare disease. The word “hantavirus” appears zero times. $MRNA closes ~$22.36.
Moderna IR ↗229 confirmed hantavirus pulmonary syndrome cases, 59 deaths, 25.7% case fatality, eight countries, mainly the Southern Cone.
PAHO alert (PDF) ↗8 cases, 6 confirmed, 3 deaths. After this, Moderna is reported to confirm early preclinical hantavirus work with USAMRIID.
WHO DON600 ↗Every claim in the rabbit hole, graded against the evidence matrix. Timing goes on the board. Causation stays in the drawer.
Official press release, presentation and transcript, searched. The company that supposedly knew everything spent its big day talking about flu shots and cost cuts.
No hits for “hantavirus,” “USAMRIID” or “Army.” No substantive mention of Korea. No exact mention of “mRNA Access.”
Moderna IR ↗Seasonal franchise (COVID, RSV, flu, flu/COVID combo, norovirus), early vaccines (CMV, EBV, Lyme), individualized neoantigen therapy with Merck, and rare disease (propionic and methylmalonic acidemia).
Manufacturing-partnership talk around national security, biodefense and “future pandemic threats.” That is boilerplate in every vaccine deck since 2020.
A stock bottoming on a cost-cutting day is the least mysterious thing in this dossier.
Left column survives a fact-check. Right column survives nothing, including a group chat with one nurse in it.
Minigenome and reverse-genetics systems, pseudotyped surrogate viruses, animal models, antigen expression, nanoparticle immunogens, rodent ecology. All of it sounds like a movie trailer. None of it, by itself, is evidence of gain-of-function, engineering or release.
Reverse genetics primer ↗No verified evidence of gain-of-function, engineering, deliberate release or lab origin was found. Andes virus is endemic in South America and lives in rodents. The boring explanation has a head start.
Research compiled in May 2026 and last checked May 12, 2026. The MV Hondius situation was still moving then; case counts may have changed since. Primary records (WHO, PAHO, CDC, patents, company IR) first, reporting second.